MX350964B - Formulaciones de agonistas del receptor de somatostatina. - Google Patents
Formulaciones de agonistas del receptor de somatostatina.Info
- Publication number
- MX350964B MX350964B MX2014014379A MX2014014379A MX350964B MX 350964 B MX350964 B MX 350964B MX 2014014379 A MX2014014379 A MX 2014014379A MX 2014014379 A MX2014014379 A MX 2014014379A MX 350964 B MX350964 B MX 350964B
- Authority
- MX
- Mexico
- Prior art keywords
- receptor agonist
- somatostatin receptor
- compositions
- forming
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones que forman una mezcla de baja viscosidad de: a) 20-50 % en peso de al menos un diacilglicerol; b) 20-54 %en peso de al menos una fosfatidil colina (PC); c) 5-15 % en peso de al menos un solvente mono-alcohólico orgánico y biocompatible; d) 1 a 20 % en peso de solvente polar e) 5 a 150 mg/ml de al menos un agonista del receptor de somatostatina de péptido que comprende pasireotida; f) opcionalmente al menos un antioxidante; en donde la relación de componentes a:b se encuentra en el intervalo de 40:60 a 54:46; en donde la preformulación forma, o tiene la capacidad de formar, al menos una estructura de fase cristalina líquida tras el contacto con fluido acuoso en exceso. La invención se refiere adicionalmente a métodos de tratamiento que comprenden la administración de tales composiciones y a dispositivos de administración precargados y kits que contienen las formulaciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/059917 WO2012160213A1 (en) | 2011-05-25 | 2012-05-25 | Controlled release peptide formulations |
US201261730613P | 2012-11-28 | 2012-11-28 | |
PCT/EP2013/060739 WO2013174978A1 (en) | 2012-05-25 | 2013-05-24 | Somatostatin receptor agonist formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014014379A MX2014014379A (es) | 2015-02-05 |
MX350964B true MX350964B (es) | 2017-09-27 |
Family
ID=49623188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014379A MX350964B (es) | 2012-05-25 | 2013-05-24 | Formulaciones de agonistas del receptor de somatostatina. |
Country Status (23)
Country | Link |
---|---|
US (2) | US11672843B2 (es) |
JP (1) | JP6374380B2 (es) |
KR (1) | KR102139080B1 (es) |
CN (1) | CN104487050B (es) |
AU (1) | AU2013265210B2 (es) |
BR (1) | BR112014029425A2 (es) |
CA (1) | CA2874367C (es) |
CL (1) | CL2014003185A1 (es) |
CO (1) | CO7160067A2 (es) |
DK (1) | DK2861209T3 (es) |
EA (1) | EA035495B1 (es) |
ES (1) | ES2834318T3 (es) |
HK (1) | HK1207985A1 (es) |
IL (1) | IL235740A0 (es) |
IN (1) | IN2014DN09831A (es) |
MA (1) | MA37672A1 (es) |
MX (1) | MX350964B (es) |
NZ (1) | NZ702028A (es) |
PE (1) | PE20150195A1 (es) |
PH (1) | PH12014502614A1 (es) |
SG (1) | SG11201407678YA (es) |
TN (1) | TN2014000483A1 (es) |
WO (1) | WO2013174978A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
DK2714004T3 (da) * | 2011-05-25 | 2024-06-10 | Camurus Ab | Peptidformuleringer med kontrolleret frigivelse |
IL295457A (en) * | 2016-09-27 | 2022-10-01 | Camurus Ab | Mixtures and formulations containing alkyl ammonium salt edta |
CN113018248B (zh) * | 2019-12-23 | 2022-07-22 | 南京清普生物科技有限公司 | 一种缓释递药*** |
CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及*** |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5340802A (en) | 1989-06-30 | 1994-08-23 | Abbott Laboratories | Peptide analog type-B CCK receptor ligands |
CA2535463A1 (en) | 1989-07-07 | 1991-01-08 | Novartis Ag | Octreotide-pamoate and its use in sustained release formulations of water soluble peptides |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
ES2133391T3 (es) | 1991-10-04 | 1999-09-16 | Gs Dev Ab | Particulas, metodo para preparar dichas particulas y usos de las mismas. |
WO1993006921A1 (en) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
EP0752855B1 (en) | 1994-03-30 | 1999-06-09 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
FR2725369B1 (fr) | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
AU702030B2 (en) | 1995-10-12 | 1999-02-11 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
CA2286052A1 (en) | 1997-04-17 | 1998-10-29 | Lise Sylvest Nielsen | A novel bioadhesive drug delivery system based on liquid crystals |
US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
SI1140148T1 (sl) | 1998-12-22 | 2006-04-30 | Lilly Co Eli | Stabilna formulacija raztopine glukagonu podobnega peptida-1 |
US6011067A (en) | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
US7008646B2 (en) | 2001-02-20 | 2006-03-07 | Patrick Thomas Spicer | Cubic liquid crystalline compositions and methods for their preparation |
US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
EP1408932A4 (en) | 2001-06-23 | 2009-02-25 | Lyotropic Therapeutics Inc | PARTICLES WITH ENHANCED SOLUBILIZATION CAPACITY |
ATE382057T1 (de) | 2001-06-28 | 2008-01-15 | Novo Nordisk As | Stabile formulierung von modifiziertem glp-1 |
AU2003201998C1 (en) | 2002-01-10 | 2012-10-25 | Imperial Innovations Limited | Modification of feeding behavior |
US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
ATE411101T1 (de) | 2003-08-04 | 2008-10-15 | Camurus Ab | Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen |
JP5518282B2 (ja) | 2003-09-01 | 2014-06-11 | ノヴォ ノルディスク アー/エス | 安定なペプチドの製剤 |
GB0322033D0 (en) | 2003-09-19 | 2003-10-22 | Camurus Ab | Composition |
WO2006075124A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
US8865021B2 (en) | 2003-11-07 | 2014-10-21 | Camurus Ab | Compositions of lipids and cationic peptides |
WO2005063213A1 (en) | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
EP1713446B1 (en) | 2004-01-23 | 2010-12-01 | Camurus Ab | Ternary non-lamellar lipid compositions |
GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
JP5127449B2 (ja) | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
CA2575906C (en) | 2004-08-04 | 2014-04-15 | Camurus Ab | Compositions forming non-lamellar dispersions |
WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
DE602005026998D1 (de) | 2005-01-14 | 2011-04-28 | Camurus Ab | Somatostatin-analog-formulierungen |
SI1845942T1 (sl) | 2005-01-14 | 2014-06-30 | Camurus Ab | Gnrh analogne formulacije |
KR101245022B1 (ko) | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
CN101309713A (zh) | 2005-11-17 | 2008-11-19 | 周吉尼克斯股份有限公司 | 用无针注射递送粘稠制剂 |
GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
AR066677A1 (es) * | 2007-05-24 | 2009-09-02 | Novartis Ag | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
ES2399651T3 (es) * | 2008-07-08 | 2013-04-02 | Novartis Ag | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
DK2714004T3 (da) * | 2011-05-25 | 2024-06-10 | Camurus Ab | Peptidformuleringer med kontrolleret frigivelse |
JP6081480B2 (ja) | 2011-12-05 | 2017-02-15 | カムルス エービー | 頑強な徐放性製剤 |
-
2013
- 2013-05-24 CA CA2874367A patent/CA2874367C/en active Active
- 2013-05-24 WO PCT/EP2013/060739 patent/WO2013174978A1/en active Application Filing
- 2013-05-24 MA MA37672A patent/MA37672A1/fr unknown
- 2013-05-24 NZ NZ702028A patent/NZ702028A/en not_active IP Right Cessation
- 2013-05-24 DK DK13724299.6T patent/DK2861209T3/da active
- 2013-05-24 ES ES13724299T patent/ES2834318T3/es active Active
- 2013-05-24 SG SG11201407678YA patent/SG11201407678YA/en unknown
- 2013-05-24 AU AU2013265210A patent/AU2013265210B2/en active Active
- 2013-05-24 KR KR1020147036398A patent/KR102139080B1/ko active IP Right Grant
- 2013-05-24 JP JP2015513209A patent/JP6374380B2/ja active Active
- 2013-05-24 BR BR112014029425A patent/BR112014029425A2/pt not_active Application Discontinuation
- 2013-05-24 MX MX2014014379A patent/MX350964B/es active IP Right Grant
- 2013-05-24 IN IN9831DEN2014 patent/IN2014DN09831A/en unknown
- 2013-05-24 CN CN201380034030.8A patent/CN104487050B/zh active Active
- 2013-05-24 PE PE2014002215A patent/PE20150195A1/es not_active Application Discontinuation
- 2013-05-24 EA EA201491928A patent/EA035495B1/ru not_active IP Right Cessation
- 2013-05-24 US US14/401,559 patent/US11672843B2/en active Active
-
2014
- 2014-11-17 IL IL235740A patent/IL235740A0/en unknown
- 2014-11-21 TN TN2014000483A patent/TN2014000483A1/fr unknown
- 2014-11-24 CL CL2014003185A patent/CL2014003185A1/es unknown
- 2014-11-24 PH PH12014502614A patent/PH12014502614A1/en unknown
- 2014-12-18 CO CO14278535A patent/CO7160067A2/es unknown
-
2015
- 2015-09-08 HK HK15108712.3A patent/HK1207985A1/xx unknown
-
2023
- 2023-04-26 US US18/307,124 patent/US20230372436A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11201407678YA (en) | 2014-12-30 |
CA2874367C (en) | 2020-08-18 |
TN2014000483A1 (en) | 2016-03-30 |
US11672843B2 (en) | 2023-06-13 |
KR20150016977A (ko) | 2015-02-13 |
US20150105332A1 (en) | 2015-04-16 |
EA201491928A1 (ru) | 2015-09-30 |
US20230372436A1 (en) | 2023-11-23 |
PH12014502614A1 (en) | 2015-01-21 |
MX2014014379A (es) | 2015-02-05 |
EA035495B1 (ru) | 2020-06-25 |
CL2014003185A1 (es) | 2015-04-24 |
ES2834318T3 (es) | 2021-06-17 |
AU2013265210A1 (en) | 2014-12-04 |
WO2013174978A1 (en) | 2013-11-28 |
JP2015520762A (ja) | 2015-07-23 |
HK1207985A1 (en) | 2016-02-19 |
AU2013265210B2 (en) | 2016-09-15 |
DK2861209T3 (da) | 2020-12-21 |
IL235740A0 (en) | 2015-01-29 |
CA2874367A1 (en) | 2013-11-28 |
KR102139080B1 (ko) | 2020-07-29 |
CN104487050B (zh) | 2019-08-20 |
NZ702028A (en) | 2016-07-29 |
IN2014DN09831A (es) | 2015-08-07 |
JP6374380B2 (ja) | 2018-08-15 |
MA37672A1 (fr) | 2016-07-29 |
BR112014029425A2 (pt) | 2017-06-27 |
CN104487050A (zh) | 2015-04-01 |
CO7160067A2 (es) | 2015-01-15 |
PE20150195A1 (es) | 2015-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013013401A (es) | Formulaciones pepticidas de liberacion controlada. | |
MX350929B (es) | Formulaciones peptidicas robustas de liberación controlada. | |
TN2014000483A1 (en) | Somatostatin receptor agonist formulations | |
MX2018003333A (es) | Formulaciones de liberacion controlada. | |
MX2013002932A (es) | Formulaciones agricolas liquidas de estabilidad mejorada. | |
CL2015003290A1 (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4). | |
ATE501710T1 (de) | Somatostatin-analog-formulierungen | |
PE20130402A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
MX2019011314A (es) | Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. | |
EA201791166A1 (ru) | Препараты с контролируемым высвобождением | |
MX2019002999A (es) | Formulaciones de analogo de prostaciclina. | |
NZ710769A (en) | Liquid menthol compositions | |
GEP20156218B (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
EA201201480A1 (ru) | Адгезионные ретардированные составы для местного применения куркумина | |
BR112015023750A2 (pt) | composição agricolamente ativa concentrada; método de preparação da composição pronta para uso; composição pronta para uso; e método para o tratamento de uma planta | |
TH1301006692A (th) | สูตรผสมเปปไทด์ที่ปลดปล่อยยาในอัตราคงที่ | |
PL412101A1 (pl) | Mieszanina lotnych związków organicznych przeznaczonych do odstraszania owadów | |
BR112018001637A2 (pt) | concentrado contendo alprostadil | |
IN2013DE00762A (es) | ||
TH161414B (th) | สูตรผสมโอปิออยด์ | |
TH162713A (th) | ยาชนิดรวมที่ประกอบรวมด้วยเจมิกลิปทินและเมตฟอร์มินและวิธีการสำหรับ การเตรียมยาชนิดรวมดังกล่าว |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |